Advertisement
Screener

CARDIFF ONCOLOGY, INC. (CRDF) Proceeds from Common Stock Issued

2.8 / 5 stars · 68/120 Roast Me

CARDIFF ONCOLOGY, INC. Proceeds from Common Stock Issued

CARDIFF ONCOLOGY, INC. (CRDF) reported Proceeds from Common Stock Issued of $212.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Cash Flow › Financing Activities

us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-11

  • CARDIFF ONCOLOGY, INC. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $44.17M.
  • CARDIFF ONCOLOGY, INC. proceeds from issuance of common stock for the quarter ending 2024-09-30 was $7.40M.
  • CARDIFF ONCOLOGY, INC. proceeds from issuance of common stock for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
  • CARDIFF ONCOLOGY, INC. proceeds from issuance of common stock for the quarter ending 2022-09-30 was $0.00.
  • CARDIFF ONCOLOGY, INC. proceeds from issuance of common stock for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
  • CARDIFF ONCOLOGY, INC. proceeds from issuance of common stock for fiscal 2024 was $53.41M.
  • CARDIFF ONCOLOGY, INC. proceeds from issuance of common stock for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
  • CARDIFF ONCOLOGY, INC. proceeds from issuance of common stock for fiscal 2021 was $34.19M, a 69.56% decline from fiscal 2020.
Period endProceeds from Issuance of Common Stock 1 monthProceeds from Issuance of Common Stock 3 monthProceeds from Issuance of Common Stock 3 month as first filedProceeds from Issuance of Common Stock 6 monthProceeds from Issuance of Common Stock 6 month as first filedProceeds from Issuance of Common Stock 9 monthProceeds from Issuance of Common Stock 9 month as first filedProceeds from Issuance of Common Stock 12 monthProceeds from Issuance of Common Stock 12 month as first filedProceeds from Issuance of Common Stock 152 monthProceeds from Issuance of Common Stock 155 monthProceeds from Issuance of Common Stock 158 monthProceeds from Issuance of Common Stock 161 monthProceeds from Issuance of Common Stock 164 monthProceeds from Issuance of Common Stock 167 monthProceeds from Issuance of Common Stock 170 monthProceeds from Issuance of Common Stock 173 monthProceeds from Issuance of Common Stock 176 month
2026-06-30$212.00K
10-Q · filed 2026-08-11
2025-12-31$0.00
10-K · filed 2026-02-24
2025-06-30$0.00
10-Q · filed 2026-08-11
2024-12-31$44.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$51.58M
derived: sum of 2 quarters · filed 2026-02-24
$53.41M
10-K · filed 2026-02-24
2024-09-30$7.40M
10-Q · filed 2024-11-07
$9.23M
10-Q · filed 2025-11-06
2024-06-30$1.80M
10-Q · filed 2024-08-08
$1.80M
10-Q · filed 2025-07-29
2023-06-30$0.00
10-Q · filed 2024-08-08
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02
$0.00
derived: sum of 2 quarters · filed 2023-03-02
$0.00
10-K · filed 2023-03-02
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$0.00
10-Q · filed 2022-11-03
2022-06-30$0.00
10-Q · filed 2022-08-04
2021-12-31$14.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02
$14.96M
derived: sum of 2 quarters · filed 2023-03-02
$34.19M
derived: sum of 3 quarters · filed 2023-03-02
$34.19M
10-K · filed 2023-03-02
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$19.23M
derived: sum of 2 quarters · filed 2022-11-03
$19.23M
10-Q · filed 2022-11-03
$113.25M
derived: sum of 4 quarters · filed 2022-11-03
2021-06-30$19.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
$19.23M
10-Q · filed 2022-08-04
$113.25M
derived: sum of 3 quarters · filed 2022-08-04
$112.72M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31$0.00
10-Q · filed 2021-05-06
$94.02M
derived: sum of 2 quarters · filed 2022-02-24
$93.50M
derived: sum of 3 quarters · filed 2022-02-24
$111.30M
derived: sum of 4 quarters · filed 2022-02-24
2020-12-31$94.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
$93.50M
derived: sum of 2 quarters · filed 2022-02-24
$111.30M
derived: sum of 3 quarters · filed 2022-02-24
$112.30M
10-K · filed 2022-02-24
$112.30M
10-K · filed 2021-02-25
2020-09-30-$523.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
$17.28M
derived: sum of 2 quarters · filed 2021-11-04
$18.28M
10-Q · filed 2021-11-04
$18.28M
10-Q · filed 2020-11-05
$22.71M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30$17.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$18.80M
10-Q · filed 2021-08-05
$18.80M
10-Q · filed 2020-08-11
$23.23M
derived: sum of 3 quarters · filed 2021-08-05
$24.72M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$1.00M
10-Q · filed 2021-05-06
$1.00M
10-Q · filed 2020-05-07
$5.43M
derived: sum of 2 quarters · filed 2021-05-06
$6.92M
derived: sum of 3 quarters · filed 2021-05-06
$9.82M
derived: sum of 4 quarters · filed 2021-05-06
2019-12-31$4.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$5.92M
derived: sum of 2 quarters · filed 2021-02-25
$8.82M
derived: sum of 3 quarters · filed 2021-02-25
$8.82M
10-K · filed 2021-02-25
2019-09-30$1.48M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$4.39M
derived: sum of 2 quarters · filed 2020-11-05
$4.39M
10-Q · filed 2020-11-05
$4.39M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30$2.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11
$2.90M
10-Q · filed 2020-08-11
$2.90M
derived: sum of 3 quarters · filed 2020-08-11
$2.90M
derived: sum of 4 quarters · filed 2020-08-11
2019-03-31$0.00
10-Q · filed 2020-05-07
$0.00
derived: sum of 2 quarters · filed 2020-05-07
$0.00
derived: sum of 3 quarters · filed 2020-05-07
2018-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27
$0.00
derived: sum of 2 quarters · filed 2020-02-27
$11.78M
10-K · filed 2020-02-27
$13.12M
10-K · filed 2019-03-06
2018-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
$11.78M
10-Q · filed 2019-11-07
2018-06-30$11.78M
10-Q · filed 2019-08-08
2017-12-31$5.09M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06
$11.62M
derived: sum of 2 quarters · filed 2019-03-06
$11.73M
10-K · filed 2019-03-06
2017-09-30$6.53M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07
$6.63M
10-Q · filed 2018-11-07
2017-06-30$106.79K
10-Q · filed 2018-08-03
2016-12-31$70.94K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26
$2.36M
derived: sum of 2 quarters · filed 2018-02-26
$2.36M
derived: sum of 3 quarters · filed 2018-02-26
$2.36M
10-K · filed 2018-02-26
$2.29M
10-K · filed 2017-03-15
2016-09-30$2.29M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
$2.29M
derived: sum of 2 quarters · filed 2017-11-09
$2.29M
10-Q · filed 2017-11-09
$2.29M
derived: sum of 4 quarters · filed 2017-11-09
2016-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09
$0.00
10-Q · filed 2017-08-09
$1.00
derived: sum of 3 quarters · filed 2017-08-09
$37.40M
derived: sum of 4 quarters · filed 2017-08-09
2016-03-31$0.00
10-Q · filed 2016-05-10
$1.00
derived: sum of 2 quarters · filed 2017-03-15
$37.40M
derived: sum of 3 quarters · filed 2017-03-15
$39.77M
derived: sum of 4 quarters · filed 2017-03-15
2015-12-31$1.00
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15
$37.40M
derived: sum of 2 quarters · filed 2017-03-15
$39.77M
derived: sum of 3 quarters · filed 2017-03-15
$61.22M
10-K · filed 2017-03-15
2015-09-30$37.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09
$39.77M
derived: sum of 2 quarters · filed 2016-11-09
$61.22M
10-Q · filed 2016-11-09
$61.22M
derived: sum of 4 quarters · filed 2017-03-15
2015-06-30$2.37M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
$23.82M
10-Q · filed 2016-08-04
$23.82M
derived: sum of 3 quarters · filed 2017-03-15
2015-03-31$21.45M
10-Q · filed 2016-05-10
$21.45M
derived: sum of 2 quarters · filed 2017-03-15
2014-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15
$0.00
10-K · filed 2017-03-15
2014-09-30$0.00
10-Q · filed 2015-11-09
2014-03-31$51.59M
10-Q · filed 2014-05-12
2013-12-31-$67.74K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10
$18.83M
10-K · filed 2016-03-10
$51.59M
10-K · filed 2014-03-17
2013-09-30$18.90M
10-Q · filed 2014-11-06
$51.65M
10-Q · filed 2013-11-14
2013-06-30$32.76M
10-Q · filed 2013-08-14
2013-03-31$32.76M
10-Q · filed 2013-05-14
2012-12-31$4.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12
$4.38M
derived: sum of 2 quarters · filed 2015-03-12
$14.43M
derived: sum of 3 quarters · filed 2015-03-12
$15.32M
10-K · filed 2015-03-12
$32.76M
10-K · filed 2013-04-01
2012-09-30-$490.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14
$10.06M
derived: sum of 2 quarters · filed 2013-11-14
$10.95M
10-Q · filed 2013-11-14
$12.01M
derived: sum of 4 quarters · filed 2014-03-17
$28.38M
10-Q · filed 2012-11-14
2012-06-30$10.06M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14
$10.95M
10-Q · filed 2013-08-14
$12.01M
derived: sum of 3 quarters · filed 2014-03-17
$12.55M
derived: sum of 4 quarters · filed 2014-03-17
$28.38M
10-Q · filed 2012-08-14
2012-03-31$889.50K
10-Q · filed 2013-05-14
$1.95M
derived: sum of 2 quarters · filed 2014-03-17
$2.49M
derived: sum of 3 quarters · filed 2014-03-17
$2.86M
derived: sum of 4 quarters · filed 2014-03-17
$18.32M
10-Q · filed 2012-05-15
2011-12-31$1.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17
$1.60M
derived: sum of 2 quarters · filed 2014-03-17
$1.97M
derived: sum of 3 quarters · filed 2014-03-17
$2.57M
10-K · filed 2014-03-17
2011-09-30$535.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14
$910.00K
derived: sum of 2 quarters · filed 2012-11-14
$1.51M
10-Q · filed 2012-11-14
2011-06-30$375.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14
$975.00K
10-Q · filed 2012-08-14
2011-03-31$600.00K
10-Q · filed 2012-05-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Vaxart, Inc. (VXRT)United States$0.080B3.84
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B